SACRAMENTO, California, June 12, 2015 /PRNewswire/ -- SynGen Inc., a company that focuses on the development and commercialization of instrument systems that harvest stem and progenitor cells from umbilical cord blood, bone marrow, peripheral blood, and cell culture, announced today that, after extensive review of competitive systems, The Anthony Nolan Cell Therapy Centre in Nottingham UK has chosen the SynGenX™-1000 System and the CryoPRO Workstation to process its umbilical cord blood units. Anthony Nolan has signed a 5-year contract with Deva Medical Electronics Ltd, SynGen Inc.'s UK distributor, for the supply of SynGen's products and all post-sales support, starting late summer 2015.
The state-of-the-art SynGenX-1000 System harvests the stem and progenitor cells from collected units of umbilical cord blood. The CryoPRO Workstation protects the precious cells as they are prepared for freezing and storage in the novel CryoPRO-2 Cryopreservation/Storage Bag Set. The SynGenX-1000 System has received 510(k) clearance from the FDA for sale in the United States, and is CE marked for sale in the UK and the European Union.
"In our hands, the SynGen system demonstrated the highest recovery of viable stem and progenitor cells of the available systems," said Dr. Susana Gomez, Head of the Anthony Nolan Cord Blood Bank and Senior Research Scientist. "We look forward to a long and productive relationship with both SynGen and Deva Medical that will benefit patients who require a transplant."
"We are proud to be associated with the prestigious Anthony Nolan Cell Therapy Centre and are pleased that their testing has demonstrated both high total nuclear cell counts (TNCs) and virtually 100% recoveries of critical CD 34+ cells in the final product using the SynGenX-1000 System," said Frank Pascale, President of the SynGen Cord Blood Business Unit. "We look forward to supporting Anthony Nolan's goal of providing them with the best possible cord blood units for transplant."
Jason Betteley, Director at Deva Medical, said, "Deva Medical and SynGen are extremely excited to have won this new 5-year contract with The Anthony Nolan Cell Therapy Centre. We are equally excited to be the distributor of the SynGenX-1000 System for SynGen throughout the EU. We continue to be extremely impressed with the high standard of expertise and professionalism of everyone at SynGen and look forward to a long relationship with both SynGen and Anthony Nolan."
About Anthony Nolan
Anthony Nolan is a non-profit charity that saves the lives of people with blood cancer by matching remarkable people willing to donate their bone marrow or cord blood to patients in desperate need of a transplant. Opened in 2008 by the UK Secretary of State for Health in the grounds of Nottingham Trent University, the Anthony Nolan Cell Therapy Centre is the first to combine cord blood storage with a research institute developing new techniques to use it. The Anthony Nolan Cell Therapy Centre processes and stores cord blood for national and international clinical transplantation centres. The centre also carries out world-class research using blood of non-clinical standard, and supplies cord blood to other approved research programmes throughout Europe.
For more information about Anthony Nolan, see www.anthonynolan.org.
About SynGen Inc.
SynGen advances regenerative medicine and other emerging applications for high-value cells by providing researchers, clinicians and manufacturers with innovative, robust systems that improve the recovery, purity and viability of stem and other clinically-important cells from umbilical cord blood, peripheral blood, bone marrow, and cell culture.
For more information about SynGen, visit the company's website at www.syngeninc.com.
Company Contact: Lee Asplund, Director of Sales and Marketing, at:
About Deva Medical
Deva Medical has been operating successfully as a UK medical devices and maintenance business since 1981. In 2012, Deva Medical began working with SynGen and subsequently created a new division within Deva exclusively to address the cord blood banking and cell therapy processing markets. It is the exclusive distributor of the new SynGenX™-1000 System within the UK and several other EU countries.
For more information about Deva Medical, visit the company's website at www.deva-medical.com.
Company Contact: Jason Betteley, Director, at:
Phone: +44 (0)1928 567571
Mobile: +44 (0)7785 290096
SOURCE SynGen Inc.